Integer (NYSE:ITGR) Downgraded to Hold Rating by Truist Financial

Truist Financial downgraded shares of Integer (NYSE:ITGR) from a strong-buy rating to a hold rating in a research report sent to investors on Monday,Zacks.com reports.

A number of other research firms have also recently issued reports on ITGR. Citigroup raised their target price on shares of Integer from $92.00 to $96.00 and gave the stock a “neutral” rating in a research note on Wednesday, July 8th. Piper Sandler downgraded shares of Integer from an “overweight” rating to a “hold” rating and set a $127.00 price objective for the company. in a research report on Monday. Raymond James Financial downgraded Integer from a “moderate buy” rating to a “hold” rating in a research report on Monday. Oppenheimer cut Integer from an “outperform” rating to a “market perform” rating in a report on Monday. Finally, Weiss Ratings restated a “hold (c)” rating on shares of Integer in a research note on Thursday, June 18th. One investment analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and twelve have issued a Hold rating to the company. According to MarketBeat.com, Integer presently has a consensus rating of “Hold” and an average price target of $103.71.

Integer Price Performance

NYSE:ITGR opened at $124.44 on Monday. The company has a quick ratio of 2.38, a current ratio of 3.75 and a debt-to-equity ratio of 0.77. The stock’s 50 day moving average price is $94.58 and its two-hundred day moving average price is $89.28. The firm has a market capitalization of $4.23 billion, a price-to-earnings ratio of 31.03, a P/E/G ratio of 2.89 and a beta of 0.61. Integer has a 12-month low of $62.00 and a 12-month high of $125.54.

Integer (NYSE:ITGR) last released its quarterly earnings data on Monday, August 3rd. The medical equipment provider reported $1.60 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.38 by $0.22. The company had revenue of $464.11 million during the quarter, compared to analysts’ expectations of $450.67 million. Integer had a return on equity of 12.83% and a net margin of 7.64%.The business’s revenue was down 2.6% on a year-over-year basis. During the same period last year, the firm posted $1.55 earnings per share. On average, analysts anticipate that Integer will post 6.04 earnings per share for the current year.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in shares of Integer by 4.0% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 21,515 shares of the medical equipment provider’s stock valued at $2,539,000 after buying an additional 837 shares during the period. Millennium Management LLC raised its holdings in Integer by 2,408.8% in the 1st quarter. Millennium Management LLC now owns 123,132 shares of the medical equipment provider’s stock valued at $14,531,000 after acquiring an additional 118,224 shares in the last quarter. Jones Financial Companies Lllp raised its holdings in Integer by 79,888.9% in the 1st quarter. Jones Financial Companies Lllp now owns 7,199 shares of the medical equipment provider’s stock valued at $850,000 after acquiring an additional 7,190 shares in the last quarter. United Services Automobile Association bought a new stake in shares of Integer during the 1st quarter valued at $258,000. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its position in shares of Integer by 4.7% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 109,316 shares of the medical equipment provider’s stock valued at $12,900,000 after acquiring an additional 4,873 shares during the period. 99.29% of the stock is owned by institutional investors.

Key Headlines Impacting Integer

Here are the key news stories impacting Integer this week:

• Positive Sentiment: KKR will pay Integer shareholders $127 per share, representing premiums of approximately 51.8% to the April 29 closing price and 28.8% to the 30-day volume-weighted average price. The cash offer provides investors with a defined exit value and is the primary reason for the stock’s rise. Integer to Be Acquired by KKR
• Positive Sentiment: Second-quarter results also exceeded expectations: adjusted earnings were $1.60 per share versus the $1.38 consensus estimate, while revenue of $464.1 million topped the $450.7 million forecast. Earnings rose from $1.55 per share a year earlier. Integer Q2 Earnings and Revenues Top Estimates
• Neutral Sentiment: The transaction is expected to close by year-end 2026, subject to shareholder and regulatory approvals. Integer’s board unanimously approved the deal, and there is no financing contingency. If completed, Integer will become private and its shares will no longer trade on the NYSE. KKR said it intends to invest in capacity, technology, innovation and employee ownership.
• Negative Sentiment: Integer withdrew its previously issued financial outlook and canceled its scheduled earnings call because of the pending acquisition. Revenue nevertheless declined 2.6% year over year, highlighting softer underlying growth despite the earnings beat. Integer Reports Second Quarter 2026 Results
• Negative Sentiment: Several law firms announced investigations into whether Integer’s directors obtained a fair price and complied with fiduciary duties in the KKR transaction. These announcements are common in takeovers but could create litigation, delay or deal-completion risks. Ademi Integer Shareholder Alert

Integer Company Profile

Integer Holdings Corporation (NYSE: ITGR) is a global provider of outsourced medical device design, development and manufacturing solutions. The company partners with leading medical technology firms to deliver complex components, subsystems and finished devices across a range of therapeutic areas. Its services encompass concept and product design, precision machining, microelectronic assembly, terminal sterilization and regulatory support, enabling customers to accelerate time to market and optimize product performance.

Integer’s product portfolio is organized into two core segments: Advanced Delivery and MedTech.